FDA Adverse Event Injury Summary report: N

FINELINE II

MDR report key: 1874094 · Received October 19, 2010

Report

Report Number
2124215-2010-19812
Event Type
Injury
Date Received
October 19, 2010
Date of Event
September 7, 2010
Report Date
September 3, 2010
Manufacturer
CPI - DEL CARIBE
Product Code
NVN
Adverse Event
Yes
Product Problem
Yes
Report Source
Manufacturer report
Reporter Occupation
MEDICAL EQUIPMENT COMPANY TECHNICIAN/REPRESENTATIVE

Narratives

Additional Manufacturer Narrative · 1

UPON RECEIPT IN OUR POST MARKET QUALITY ASSURANCE LABORATORY, A THOROUGH EVALUATION OF THE LEAD WAS PERFORMED. RESISTANCE TESTING WAS PERFORMED WHICH CONFIRMED THE ELECTRICAL CONTINUITY OF THE LEAD. LABORATORY TESTING CANNOT CONFIRM THE OBSERVED CLINICAL OBSERVATION OF DISLODGEMENT. HOWEVER, EVIDENCE AND PAST EXPERIENCE SUGGESTS THAT LEAD DISLODGEMENT CAN BE THE RESULT OF UNIQUE PATIENT PHYSIOLOGY AND /OR IMPLANT TECHNIQUE (WHICH IS OFTEN DICTATED BY PATIENT ANATOMY). LEAD DISLODGEMENT IS A POTENTIAL COMPLICATION OF IMPLANTABLE PACING AND IS DESCRIBED IN DEVICE LABELING. BOSTON SCIENTIFIC CRM WILL CONTINUE TO MONITOR FOR SIMILAR EVENTS TO ENSURE THAT NO LEAD DISPLAYS AN ABNORMAL RATE OF OCCURRENCE. NO OTHER ADVERSE EVENTS HAVE BEEN REPORTED. THIS ISSUE WILL BE RE-EVALUATED IF ADDITIONAL INFORMATION IS RECEIVED.

Description of Event or Problem · 1

BOSTON SCIENTIFIC CRM RECEIVED INFORMATION THAT THIS PATIENT HAD EXPERIENCED A SYNCOPAL EPISODE. IT WAS OBSERVED THAT THIS RIGHT VENTRICULAR LEAD WAS EXHIBITING INCREASED THRESHOLD MEASURMENTS AND DECREASED IMPEDANCE MEASUREMENTS DUE TO DISLODGEMENT. THEREFORE, A REVISION PROCEDURE WAS PERFORMED AND THE LEAD WAS REMOVED FROM SERVICE AND SUCCESSFULLY REPLACED.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 FINELINE II IMPLANTABLE LEAD NVN CPI - DEL CARIBE 4470

Patients

Seq Age Sex Outcome Treatment
1 67 YR 4470| 4469| S404| 4087